Erytech Pharma SA, which publically offered its shares for the first time in April 2013, has returned to the Paris Euronext exchange for €30 million in an offering that was 68% subscribed by US institutions. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
